Search

Search results

73 results found

TOPAZ

TOPAZ: A Randomized, Placebo-controlled Trial of Zoledronic Acid for Prevention of Fractures in Patients with Parkinson’s Disease The purpose of this study is to evaluate if a drug called Zoledronic Acid will reduce the risk of bone fractures among people with Parkinson’s disease. The study drug is...

LUMA Study

LUMA: Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease The purpose of this study is to test an investigational drug called BIIB122 to see if it may slow the progression of PD. Key...

Ask the Experts: Daniel Press, MD

Update on Preventing and Treating Cognitive Symptoms in Parkinson’s Disease By Daniel Press, MD; Chief, BIDMC Division of Cognitive Neurology; Associate Professor of Neurology, Harvard Medical School

Atypical Parkinsonism Program

Experts from the Parkinson's Disease and Movement Disorders Center at BIDMC are leaders in the diagnosis, management and research of Atypical Parkinsonian Syndromes. These syndromes are a group of rare neurological diseases that share some of the signs and symptoms of Parkinson's disease, but with...